Managing Pharmacovigilance in Digital Health Initiatives

Posted 14 August 2015

placeholder+image This article analyzes adverse event reporting obligations and identifies ways to reduce regulatory risk and cost associated with digital health initiatives.

Share this article:

Categories: Prescription drugs, Postmarket surveillance, Articles, Features, US, FDA

Tags: pharmacovigilance, pharmaceutical, adverse events, adverse event reporting, digital health

Regulatory Exchange: Latest Updates From the Community